跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
李 岡遠
教授
,
胸腔內科
合聘教授
,
臨床醫學研究所
合聘教授
,
國際醫學研究碩博士學位學程
合聘教授
,
細胞治療與再生醫學國際博士學位學程
合聘教授
,
臨床基因體學暨蛋白質體學碩士學位學程
合聘教授
,
轉譯醫學博士學位學程
主任
,
臺北醫學大學胸腔醫學研究中心
成員
,
臺北醫學大學生醫器材研究中心
成員
,
臺北醫學大學細胞治療與再生醫學研究中心
主治醫師
,
衛生福利部雙和醫院
https://orcid.org/0000-0002-1203-4094
電子郵件
leekangyun
tmu.edu
tw
h-index
7412
引文
38
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2025
每年研究成果
概覽
指紋
網路
專案
(34)
研究成果
(223)
資料集
(2)
類似的個人檔案
(12)
指紋
查看啟用 Kang-Yun Lee 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Lung Cancer
83%
Neoplasm
67%
Non Small Cell Lung Cancer
65%
Malignant Neoplasm
65%
Epidermal Growth Factor Receptor
64%
Asthma
56%
Lung Adenocarcinoma
38%
Inflammation
37%
Sleep Disordered Breathing
34%
Immunotherapy
31%
Emphysema
30%
Disease
29%
Cohort Study
27%
Protein Tyrosine Kinase Inhibitor
25%
Pleura Effusion
24%
Chemotherapy
23%
Mouse
21%
Durvalumab
19%
Vaccination Policy
19%
Pneumonia
17%
Long Term Exposure
16%
Overall Survival
16%
Sleep Disorder
14%
Tumor Necrosis Factor
14%
Phosphotransferase
13%
Epidermal Growth Factor Receptor Kinase Inhibitor
13%
Cisplatin
13%
SARS Coronavirus
13%
Adverse Event
13%
Biological Marker
12%
Tumor Growth
12%
Drug Resistance
12%
Lung Disease
12%
Combination Therapy
12%
Multiple Organ Failure
11%
Progression Free Survival
10%
Nitrogen Dioxide
10%
Lung Tuberculosis
10%
Apnea
10%
Symptom
10%
Oncoprotein
10%
Sepsis
9%
Respiratory Failure
9%
Malignant Pleura Effusion
9%
Bevacizumab
9%
Digestive System Function Disorder
9%
Growth Factor
9%
Epiregulin
9%
Polysaccharide
9%
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
95%
Lung Cancer
70%
Epidermal Growth Factor Receptor
41%
Non Small Cell Lung Cancer
36%
Obstructive Sleep Apnea
34%
Neoplasm
29%
Cohort Analysis
29%
Asthma
28%
Diagnosis
28%
Particular Matter 2.5
25%
Lung Adenocarcinoma
25%
Diagnostic Accuracy
22%
Atmospheric Aerosol
22%
Bronchoscopy
21%
Influenza Vaccination
19%
Endobronchial Ultrasonography
19%
Durvalumab
19%
Disease
18%
Emphysema
18%
T Cell
18%
In Vitro
17%
Malignant Neoplasm
17%
Epithelial Cell
17%
Neutrophil
16%
Macrophage
15%
Metastatic Carcinoma
15%
Pneumonia
15%
Cancer Cell
15%
Lung Tuberculosis
15%
Tyrosine-Kinase Inhibitor
14%
Hazard Ratio
14%
Smoking
14%
Meta-Analysis
14%
Eosinophilic
13%
Pleura Effusion
13%
Odds Ratio
12%
Sleep Quality
12%
Overall Survival
12%
Symptom
11%
Upregulation
11%
Transbronchial Aspiration
11%
Quality of Life
11%
Fine Particulate Matter
11%
Gene Expression
10%
Programmed Cell Death
10%
Respiratory Disease
10%
Forced Expiratory Volume
10%
Multiple Organ Dysfunction Syndrome
9%
Sepsis
9%
Biological Marker
9%
Immunology and Microbiology
Neutrophil
32%
Particulate Matter
32%
Promoter Region
32%
Peripheral Blood Mononuclear Cell
30%
Asthma
29%
Mouse
28%
T Cell
27%
Forced Expiratory Volume
24%
Macrophage
21%
Interleukin-1
20%
Myeloid-Derived Suppressor Cell
19%
Chemokine
18%
Immunotherapy
17%
Immunocompetent Cell
17%
Signal Transduction
17%
Airway Smooth Muscle Cell
17%
Cancer Cell
16%
Upregulation
16%
Smooth Muscle
16%
Programmed Death 1 Ligand 1
15%
Tumor Necrosis Factor
15%
Pulmonary Inflammation
14%
Systemic Inflammation
14%
Normal Human
14%
Lung Function
13%
Forced Vital Capacity
12%
Gene Expression
12%
Interleukin-6
12%
Immune Response
12%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Oxidative Stress
11%
Interferon Type I
11%
down Regulation
11%
COVID-19
11%
Cell Migration
11%
Inflammation Response
11%
Eosinophil
10%
Cytokine
9%
Chromatin Immunoprecipitation
9%
Oncogene
9%
Hippo Signaling
9%
Humidity
9%
Mesenchymal Stem Cell
9%
Histone Modification
9%
Immunosurveillance
9%
Lung Diffusion Capacity
9%
CD14
9%
Umbilical Cord
9%
Alveolar Macrophage
9%
Lymphocyte
8%
